Medtronic (MDT)
NYSE: MDT
· Real-Time Price · USD
92.40
0.42 (0.46%)
At close: Aug 15, 2025, 12:05 PM
Medtronic Revenue Breakdown
| Period Ending | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | Apr 28, 2017 | Apr 29, 2016 | Apr 24, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac and Vascular Group Revenue | 12.48B | 11.83B | 11.57B | 11.42B | 10.47B | 11.51B | 11.35B | 10.5B | 10.2B | 9.36B |
| Cardiac and Vascular Group Revenue Growth | +5.49% | +2.23% | +1.31% | +9.12% | -9.01% | +1.33% | +8.15% | +2.96% | +8.92% | n/a |
| Diabetes Group Revenue | 2.75B | 2.49B | 2.26B | 2.34B | 2.37B | 2.39B | 2.14B | 1.93B | 1.86B | 1.76B |
| Diabetes Group Revenue Growth | +10.73% | +9.99% | -3.25% | -1.27% | -0.96% | +11.73% | +11.05% | +3.38% | +5.79% | n/a |
| Medical Surgical Revenue | 8.41B | 8.42B | 8.43B | 9.14B | n/a | n/a | n/a | n/a | n/a | n/a |
| Medical Surgical Revenue Growth | -0.12% | -0.19% | -7.75% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Neuroscience Group Revenue | 9.85B | 9.41B | 8.96B | 8.78B | n/a | n/a | n/a | n/a | n/a | n/a |
| Neuroscience Group Revenue Growth | +4.68% | +4.99% | +1.99% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | Apr 28, 2017 | Apr 29, 2016 | Apr 24, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ireland Revenue | 116M | 16.56B | 16.37B | 16.13B | 15.53B | 14.92B | 16.19B | 85M | 34.64B | 17.58B | 12.13B |
| Ireland Revenue Growth | -99.30% | +1.15% | +1.48% | +3.92% | +4.05% | -7.87% | +18951.76% | -99.75% | +97.06% | +44.97% | n/a |
| Total Other Countries, Excluding United States And Ireland Revenue | 16.25B | 113M | 98M | 101M | 100M | 85M | 91M | 13.99B | n/a | n/a | n/a |
| Total Other Countries, Excluding United States And Ireland Revenue Growth | +14280.53% | +15.31% | -2.97% | +1.00% | +17.65% | -6.59% | -99.35% | n/a | n/a | n/a | n/a |
| United States Revenue | 17.17B | 15.69B | 14.76B | 15.45B | 14.49B | 13.91B | 14.27B | 15.88B | n/a | n/a | n/a |
| United States Revenue Growth | +9.45% | +6.32% | -4.49% | +6.62% | +4.18% | -2.54% | -10.10% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | Apr 27, 2018 | Jan 26, 2018 | Oct 27, 2017 | Jul 28, 2017 | Apr 28, 2017 | Jan 27, 2017 | Oct 28, 2016 | Jul 29, 2016 | Apr 29, 2016 | Jan 29, 2016 | Oct 30, 2015 | Jul 31, 2015 | Apr 24, 2015 | Jan 23, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.72B | 2.72B | 2.76B | 2.65B | 2.77B | 2.67B | 2.69B | 2.61B | 2.62B | 2.62B | 2.62B | 2.57B | 2.57B | 2.56B | 2.62B | 2.55B | 2.6B | 2.54B | 2.6B | 2.42B | 2.36B | 2.59B | 2.62B | 2.54B | 2.62B | 2.6B | 2.6B | 2.6B | 2.55B | 2.52B | 2.54B | 2.58B | 2.48B | 2.39B | 2.42B | 2.43B | 2.36B | 2.32B | 2.34B | 2.45B | 2.4B | 1.49B |
| Selling, General, and Administrative Revenue Growth | +0.11% | -1.45% | +3.84% | -3.98% | +3.44% | -0.48% | +2.79% | -0.11% | +0.04% | -0.08% | +1.95% | -0.08% | +0.31% | -2.07% | +2.67% | -1.85% | +2.29% | -2.42% | +7.57% | +2.46% | -8.81% | -1.26% | +3.03% | -2.94% | +0.92% | -0.35% | +0.31% | +1.76% | +1.15% | -0.63% | -1.59% | +4.07% | +3.81% | -1.16% | -0.49% | +2.88% | +1.86% | -1.11% | -4.33% | +1.87% | +61.67% | n/a |
| Research and Development Revenue | 684M | 675M | 697M | 676M | 675M | 695M | 698M | 668M | 639M | 688M | 676M | 692M | 652M | 657M | 676M | 750M | 632M | 601M | 639M | 621M | 567M | 573M | 603M | 587M | 594M | 561M | 590M | 585M | 592M | 559M | 556M | 548M | 553M | 530M | 554M | 556M | 575M | 546M | 545M | 558M | 528M | 373M |
| Research and Development Revenue Growth | +1.33% | -3.16% | +3.11% | +0.15% | -2.88% | -0.43% | +4.49% | +4.54% | -7.12% | +1.78% | -2.31% | +6.13% | -0.76% | -2.81% | -9.87% | +18.67% | +5.16% | -5.95% | +2.90% | +9.52% | -1.05% | -4.98% | +2.73% | -1.18% | +5.88% | -4.92% | +0.85% | -1.18% | +5.90% | +0.54% | +1.46% | -0.90% | +4.34% | -4.33% | -0.36% | -3.30% | +5.31% | +0.18% | -2.33% | +5.68% | +41.55% | n/a |